New division to develop and produce exclusive CBD products initially for dermatology and gerontology marketsDr. Drore Eisen, an accomplished dermatologist with over 30 years of practice, joins as Medical Director of Stem Medical HoldingsBOCA RATON, Fla., Aug. 22, 2019 (GLOBE NEWSWIRE) — Stem Holdings, Inc. (OTCQB: STMH CSE: STEM) (“Company” or “Stem”), a leading vertically-integrated cannabis company with state-of-the-art cultivation, processing, extraction, retail, and distribution operations, announced today the launch of Stem Medical Holdings (“SMH”), a new division focused on cannabidiol (CBD), an active ingredient in cannabis. SMH will develop, produce and market exclusive medical CBD products initially for dermatology and gerontology, with plans to penetrate additional medical product markets. In their July 2019 report, Brightfield Group, a research firm focused on the legal CBD and cannabis industries, estimates the U.S. CBD market will grow over 700% in 2019 to $5 billion from $620 million in 2018 and reach $23.7 billion by 2023.Drore Eisen, M.D., D.D.S., will oversee the newly formed SMH division, as Medical Director, bringing more than 30 years of medical experience to the role. Fusing Stem’s proprietary cannabis strains cultivated for quality and efficacy for many years with the world-class research and expertise of Dr. Eisen, SMH intends to create and market medical CBD products consistent with Stem’s mission and standards of supporting the health and happiness of people“We are very pleased to welcome Dr. Eisen and to launch Stem Medical Holdings to serve this market with unique products,” said Mr. Adam Berk, Chief Executive Officer of Stem. “Dr. Eisen brings decades of experience in the dermatology and gerontology fields. We are confident that he will lead our medical division to further position and drive growth for Stem as a pioneer in the industry with differentiated medical cannabis offerings that appeal to all consumers seeking its medical benefits.”Dr.